AstraZeneca
oral factor portfolio | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
24 of 49
Related slides by other companies
Ocuphire Pharma
Investor Presentation
August 2023
global partnership with for million funding for potentially all and commercialization for all indications globally million in regulatory and sales milestones first potential million milestone payment on approval in tiered double digit royalties through | Ocuphire Pharma
Crowdstrike
Investor Presentation
March 2023
long term tam evolution | Crowdstrike
argenx SE
Results
March 2022
global portfolio | argenx SE
Alkermes
Investor Day
March 2021
potential indications in neurodegenerative and disorders with cognitive deficits indications that share common of synaptic dysfunction in hippocampus with deficits in cognition includes certain autism spectrum disorders with reduced synaptic density initial clinical focus on rare and orphan diseases with potential expedited development pathways plan to select lead indications based on preclinical and human data potential indications focused on rare and orphan diseases neurodegenerative disease dementia in down syndrome syndrome syndrome syndrome tuberous sclerosis complex pay by | Alkermes
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights